Cohen Mikhal E, Shechter Yosef, Dominko Melania, Shulman Elena, Dinur Tama, Revel-Vilk Shoshana, Eichel Roni, Yahalom Gilad, Becker-Cohen Michal
Department of Neurology, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
The Movement Disorders Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Int J Mol Sci. 2025 May 30;26(11):5258. doi: 10.3390/ijms26115258.
Parkinson's disease (PD) associated with mutations-recently termed Sidransky syndrome-differs from idiopathic PD (iPD) by earlier onset, more rapid progression, and higher rates of non-motor symptoms. Our objective was to assess whether mutations contribute to olfactory dysfunction in PD and in asymptomatic carriers of the mutation. We compared olfactory and motor functions in 119 participants: Sidransky syndrome (n = 18), iPD (n = 30), variant carriers without PD (n = 21), Gaucher disease patients (n = 20), and healthy controls (n = 30). All were evaluated with the Brief Smell Identification Test (BSIT) and the motor part of the Movement Disorders Society Unified PD Rating Scale (MDS-mUPDRS). Mean age was 59.2 ± 11.7 years. Mean disease duration was 2.5 ± 2.2 years in Sidransky syndrome and 5.4 ± 4.9 years in iPD. We found that both PD groups had significantly lower BSIT scores than non-PD groups ( < 0.001), particularly for leather, smoke, natural gas, pineapple, clove, rose, and lemon. Sidransky syndrome patients scored lower than iPD patients ( = 0.04). No significant olfactory deficits were observed in carriers or Gaucher patients without PD. We conclude that hyposmia is more pronounced in Sidransky syndrome than in iPD. However, normal olfaction in non-parkinsonian carriers suggests that variants alone do not account for olfactory loss in PD. Hyposmia likely reflects broader PD pathology rather than a direct effect of the mutation.
帕金森病(PD)与突变相关——最近被称为西德兰斯基综合征——与特发性帕金森病(iPD)不同,其发病更早、进展更快且非运动症状发生率更高。我们的目的是评估这些突变是否导致PD患者以及该突变的无症状携带者出现嗅觉功能障碍。我们比较了119名参与者的嗅觉和运动功能:西德兰斯基综合征患者(n = 18)、iPD患者(n = 30)、无PD的突变携带者(n = 21)、戈谢病患者(n = 20)和健康对照者(n = 30)。所有参与者均接受简易嗅觉识别测试(BSIT)和运动障碍协会统一PD评定量表运动部分(MDS - mUPDRS)的评估。平均年龄为59.2±11.7岁。西德兰斯基综合征患者的平均病程为2.5±2.2年,iPD患者为5.4±4.9年。我们发现,两个PD组的BSIT得分均显著低于非PD组(P < 0.001),尤其是在皮革、烟、天然气、菠萝、丁香、玫瑰和柠檬气味方面。西德兰斯基综合征患者的得分低于iPD患者(P = 0.04)。在无PD的突变携带者或戈谢病患者中未观察到明显的嗅觉缺陷。我们得出结论,西德兰斯基综合征患者的嗅觉减退比iPD患者更明显。然而,非帕金森病的突变携带者嗅觉正常表明,仅突变本身并不能解释PD患者的嗅觉丧失。嗅觉减退可能反映了更广泛的PD病理变化,而非该突变的直接影响。